Innovation Pharmaceuticals Inc (IPIX)

[DaubersUP]

Kevetrin Fact: from phase 1 trial

IPIX had p21 biomarkers observed for the first 31 patients. P21 is a biomarker to read activation of P53 (in my terms)

Here are first 31 patients- remember dosing was ONCE a week for 3 weeks!!!!

Cohort 0 - 3 patients - 10mg
Cohort 1 - 4 patients - 20mg
Cohort 2 - 3 patients - 30mg
Cohort 3 - 5 patients - 50mg
Cohort 4 - 3 patients - 75mg
Cohort 5 - 3 patients - 110mg
Cohort 6 - 3 patients - 165mg
Cohort 7 - 4 patients - 215mg
Cohort 8 - 8 patients - 350mg. (Only 3 of these were included in data)


So! Results;
21 of 31 patients had an INCREASE in p21 expression (68%)
15 of those 21 had ATLEAST a 10% increase

Again, the first 3 cohorts (10 patients) were only up to 30mg m2. And this was only ONCE A WEEK dosing for 3 weeks.


We now are dosing 3 times a week and starting at 250mg m2 and 350mg m2


I will bet my shares this phase 2 trial has some pretty interesting data!!!!